Novo Nordisk 's ( NVO +2.93%) shareholders must be happy to see 2025 finally come to a close. It was not a good year for the ...

Viking Therapeutics remains a compelling obesity drugs contender, despite being in the pre-commercial phase. VKTX's ...

Madrigal’s Rezdiffra tops $1B run-rate in MASH, but losses and rising GLP-1/FGF21 competition may cap upside into 2026. See ...

Major stock indexes closed mostly higher Friday to commence the new year of trading, although the Nasdaq's losing streak ...

That's no longer the case. A poor run to end the year, including a complete no-show in the CFP quarterfinal loss to Indiana, ...

The company's market capitalization has plummeted by approximately $6.6 billion over the past 6 days and is currently valued ...

The stock boasts the one year return of 34.3%, in contrast to 16.4% for the S&P 500. This situation necessitates a ...

Figma went public at $33 last July and currently trades at approximately $37. UiPath went public at $56 in April 2021, but it ...

Wall Street made ​a ‌stellar comeback from April's lows when Trump's 'Liberation ‍Day' tariffs sparked a meltdown in ⁠global ...

Wall Street is slipping on the final day of trading for 2025, a banner year for markets that was driven by both optimism and ...

The US stock market just achieved something so rare that it’s only happened six times since the 1940s: three consecutive years of double-digit gains.